A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma. READ MORE
A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma.
Some oncologists may be more likely to prescribe certain cancer medicines when they receive payments from the companies that make these drugs.
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.
Research presented at the 2018 BMT Tandem Meetings showed that potential role of immune checkpoint inhibitors in the post-transplant setting for patients with relapsed or large B-cell lymphomas.
The international workshop on CLL updated the prognostic criteria for their consensus guideline to include all of the following EXCEPT mutational status in which gene?
The National Comprehensive Cancer Network updated their induction and consolidation treatment recommendations for low-risk and high-risk acute myeloid leukemia.
From December 9-12, 2017, the American Society of Hematology hosted its Annual Meeting and Exposition in Atlanta, Georgia. The meeting provided an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology as well as to network with top minds in the field.